Open AccessFOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Author(s) -
Jean-Florian Guion-Dusserre,
Véronique Lorgis,
Julie Vincent,
Leila Bengrine,
François Ghiringhelli
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i7.2096
Subject(s) - folfiri , medicine , bevacizumab , irinotecan , folinic acid , gastroenterology , chemotherapy , fluorouracil , response evaluation criteria in solid tumors , regimen , chemotherapy regimen , surgery , progressive disease , colorectal cancer , cancer
To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma.